Quantcast

FDAAdvisoryCommittee.Com to Webcast Dec. 1-2 Reviews of Proctor & Gamble’s Sexual Dysfunction Drug Intrinsa, Ilex’ Clolar for Leukemia, and Inex/Enzon’s Marqibo for Lymphoma

November 30, 2004

CHEVY CHASE, Md., Nov. 30 /PRNewswire/ — Breakthrough FDAAdvisoryCommittee.com Webcasts on Dec 1-2 will provide live audio/video access to Food and Drug Administration committee reviews of three new drugs: Ilex’ Clolar (Leukemia), Inex/Enzon’s Marqibo (Hodgkin’s Lymphoma); and Proctor & Gamble’s Intrinsa (female sexual dysfunction).

Dec. 1, 2004

FDA Oncologic Drugs Advisory Committee Webcast

8:00 a.m. EST

http://www.fdaadvisorycommittee.com/

Watch live on Dec. 1 as FDA’s Oncological Drugs Advisory Committee decides whether to recommend approval of two new drugs, including a product that would be the first in more than 10 years with original labeling for pediatric leukemia.

Ilex’ Clolar is undergoing priority review by FDA and is indicated for treatment of refractory or relapsed acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) in pediatric patients.

The second drug to be reviewed Dec. 1 is Inex/Enzon’s Marqibo, indicated for treatment of relapsed aggressive non-Hodgkin’s lymphoma in patients previously treated with at least two combination chemotherapy regimens.

Dec. 2, 2004

FDA Reproductive Health Drugs Advisory Committee Webcast

8:00 a.m. EST

http://www.fdaadvisorycommittee.com/

On Dec. 2, find out firsthand if FDA’s Reproductive Health Drugs Advisory Committee recommends approval of the first treatment for female sexual dysfunction, Proctor & Gamble’s Intrinsa.

Intrinsa is a transdermal testosterone patch indicated for the treatment of hypoactive sexual desire disorder in surgically menopausal women receiving concomitant estrogen therapy.

Watch FDAAdvisoryCommittee.com’s high-quality audio/video webcasts for complete gavel-to-gavel coverage, including:

* Company presentations with slides of clinical trial data

* FDA scientific and statistical reviews

* Committee deliberations and recommendations

To register for the Dec. 1 and Dec. 2 webcasts, please visit http://www.fdaadvisorycommittee.com/. The meetings can be watched live or in a post-meeting archive format.

Or bring a group together for a live videoconferencing feed from FDAAdvisoryCommittee.com. Videoconference viewers receive a free DVD or videotape recording of the meeting. DVDs and videotapes also are available for individual sale. To order videoconferencing, videotapes or DVDs, call 800-627-8171 or email webcasthelp@fdcreports.com.

And sign up for FDAAdvisoryCommittee.com’s FREE email alert service to receive the most up-to-date advisory committee news and information from the editors of “The Pink Sheet.” Sign up for your no-cost, no-obligation subscription at http://www.fdaadvisorycommittee.com/.

FDAAdvisoryCommittee.com is produced by FDC Reports: a division of the Elsevier Company. Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, the company publishes more than 1,800 journals and 2,200 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (http://www.sciencedirect.com/) and MD Consult (http://www.mdconsult.com/) bibliographic databases, online reference works and subject specific portals.

FDC Reports

CONTACT: Ralph Powe of FDC Reports, +1-800-627-8171, orwebcasthelp@fdcreports.com

Web site: http://www.fdcreports.com/http://www.fdaadvisorycommittee.com/http://www.mdconsult.com/http://www.sciencedirect.com/




comments powered by Disqus